24 May 2016 - The annual report states the TGA registered 35 new medicines in 2015.

Whilst the TGA has deemed all of them as being "new medicines', some of them are not totally 'new' and some are not 'medicines' but rather 'vaccines', 'blood products' or 'cellular therapies.'

• The TGA has registered many influenza vaccines over the years be they monovalent, trivalent and quadrivalent.  Optaflu (a new trivalent influenza vaccine) has been entered in the MAESTrO database as a new formulation.
• Sevelamer as the hydrochloride salt (Renagel) has been registered by the TGA since June 2005 so sevelamer carbonate (Renvela) has been entered in the MAESTrO database as a new formulation.
• Human albumin has been registered by the TGA for many years, so human albumain (Albunate 20) has been entered in the MAESTrO database as a new formulation.
• Human papilloma virus vaccine has been registered by the TGA in bivalent and quadrivalent forms.  Human papilloma virus vaccine (9 valent) has been entered in the MAESTrO database as a new formulation.
• Talimogene laherparepvec (Imlygic) has been entered in the MAESTrO database as a new cellular therapy.